Just weeks after 2015 country approval of Cook Medical’s Zenith Alpha abdominal endovascular graft, the University of Western London Health Sciences Centre in London, Ontario, has treated the first patient with the device as part of Cook’s Canada commercial launch.
“We would like to the thank Cook for the opportunity to place the first Cook Alpha abdominal aortic aneurysm endograft in North America,” said Adam Power, assistant professor and programme director of vascular surgery at University of Western London Health Sciences Centre.
Zenith Alpha is indicated for endovascular treatment of patients with abdominal aortic or aortoiliac aneurysms having vascular anatomy suitable for endovascular repair. These indications are aligned with the terms of market authorisation.
The introduction system features an ergonomic design and requires fewer procedural steps than previous designs to deploy the device without sacrificing the precision and control of the Zenith platform. The device also allows for wider patient applicability because of its lower profile introduction system, three-piece modular design and broad range of sizes.
“The lower profile device is designed to help physicians provide the benefits of endovascular repair to more patients,” said Nicky James, vice president and global business unit leader for Cook Medical’s Aortic Intervention division.
